Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Remicade Psoriasis Approval Marks Debut Of Centocor Dermatology Sales Force

This article was originally published in The Pink Sheet Daily

Executive Summary

J&J subsidiary also anticipates eventually using the sales force for another psoriasis product it has in its pipeline.

You may also be interested in...



Remicade Ulcerative Colitis Indication Expands To Maintenance Therapy

Remicade becomes the only biologic indicated for inducing and maintaining clinical remission of ulcerative colitis and Crohn’s disease, according to Centocor.

Remicade Ulcerative Colitis Indication Expands To Maintenance Therapy

Remicade becomes the only biologic indicated for inducing and maintaining clinical remission of ulcerative colitis and Crohn’s disease, according to Centocor.

Abbott To Seek Humira Psoriasis Indication In 2007

The three-arm Phase III trial “exceeded” Abbott’s expectations and indicates Humira is first biologic treatment “to demonstrate superiority over methotrexate,” company says.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel